The past three and a half years, and arguably longer, there has been something of a dark night passing over direct to consumer (DTC) personal genomics. The regulatory issues have been unclear to unfavorable. If you have read this blog you know 23andMe‘s saga with the Food and Drug Administration. It looks like 2017 DTC is … Continue reading Direct-to-consumer genomics, it’s back on!